Chronic kidney disease

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 22, 2022
Chronic kidney disease, Offering, Company, Therapy, Mission statement, NASDAQ, R1S, SUV, Patient, Adult, Annual report, Register, Kidney, Lists of schools in England, Grab, Anemia, Celsius, GLOBE, Phage r1t holin family, Program, Defendant, News, IPO, MACE, AKBA, Registration statement, Real estate, Security (finance), Audit, Pharmaceutical industry, Risk management, Online gambling, Akebia, Rivian, P.C

As a result, the price of the Companys shares was artificially and materially inflated at the time of the Offering.

Key Points: 
  • As a result, the price of the Companys shares was artificially and materially inflated at the time of the Offering.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • For more information on the Celsius class action go to: https://bespc.com/cases/CELH
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AKBA

Retrieved on: 
Monday, March 21, 2022
Chronic kidney disease, Company, Therapy, LLP, NASDAQ, Complaint, Lists of action films, Pomerantz, District court, Adult, Kidney, Court, Lists of schools in England, Anemia, Securities Exchange Act of 1934, Person, GLOBE, Defendant, Program, News, Ext, SEC Rule 10b-5, MACE, AKBA, Patient, Pharmaceutical industry, Akebia

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

OneLegacy Webinar Explores Chronic Kidney Disease and the Need for Kidney Donation & Transplantation Among Communities of Color

Retrieved on: 
Thursday, March 31, 2022
Diabetes, Health, Surgery, Chronic kidney disease, DMV, Health equity, African Americans, National Kidney Foundation, Population, Kidney failure, Hispanic, White, Transplant, Death, Kidney, Culture, Hispanic and Latino Americans, Color, Hospital, Kidney disease, Health, Prevalence, Diabetes, Policy, List of diplomatic missions of Mexico, Eye, Social media, Univision, Dentistry, Pharmaceutical industry, Kern

The high prevalence of chronic kidney disease and the need for kidney donation and transplantation in communities of color was the subject of a timely and important webinar conducted yesterday by OneLegacy.

Key Points: 
  • The high prevalence of chronic kidney disease and the need for kidney donation and transplantation in communities of color was the subject of a timely and important webinar conducted yesterday by OneLegacy.
  • Featured speaker at the webinar was Morgan Reid, director of transplant policy & strategy for the National Kidney Foundation.
  • In that role, Reid advocates for health equity to ensure that each person diagnosed with chronic kidney disease has an equal opportunity for kidney transplant access.
  • She has been an advocate for saving lives through donation and transplantation since she received her own kidney transplant in 2007.

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Retrieved on: 
Thursday, March 31, 2022
Health, Research, Pharmaceutical, Cardiology, Science, Biotechnology, Chronic kidney disease, Company, Risk, Therapy, Exercise, Journal, United States Patent and Trademark Office, Heart, Population, Splanchnic, PAH, Patent, Marketing, Hypertensive emergency, Heart Failure Society of America, Pulmonary hypertension, No, Board, TNX-102, Stomach, Culture, Cros, SEC, Program, Research, Patient, Cardiovascular disease, Levosimendan, Heart failure, U.S. Securities and Exchange Commission, USPTO, Board of directors, PH, OLE, Pharmacotherapy, IV, Safety, Stroke, American College, Orion Corporation, ATP, Nasdaq, COVID-19, Time, Imatinib, CRO, KOL, Annual report, Uncertainty, Disease, Security (finance), Heart failure with preserved ejection fraction, Pharmaceutical industry, Online gambling, Tenax

On January 12, announced that the United States Patent and Trademark Office (USPTO) granted Tenax a patent (No.

Key Points: 
  • On January 12, announced that the United States Patent and Trademark Office (USPTO) granted Tenax a patent (No.
  • In January 2021, Tenax purchased PHPrecisionMed Inc., a clinical stage biotechnology company focused on pulmonary hypertension, reflected in the operating results for the year ended December 31, 2021.
  • Tenax Therapeutics has North American rights to develop and commercialize oral (TNX-103) and subcutaneous (TNX-102) formulations of levosimendan.
  • Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.

Mission Therapeutics Authorised to Initiate First Clinical Trial for Lead DUB Program, MTX652, in Kidney Disease

Retrieved on: 
Thursday, March 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Chronic kidney disease, Mitochondrion, Company, Risk, Therapy, Idiopathic pulmonary fibrosis, Neurodegeneration, Trial of the century, Death, Sofinnova, Clinical trial, Pharmacokinetics, CDC, Degenerative disease, CMO, Kidney, Research, Acute kidney injury, AbbVie, Cardiovascular disease, Kidney disease, Laboratory, AKI, Ubiquitin, DUB, Mitochondrial disease, Safety, IP Group, CKD, Drug discovery, Medicare, Fibrosis, Enzyme, Dub, University, Patient, Muscular dystrophy, Pharmaceutical industry

Specific kidney cells are rich in mitochondria and highly vulnerable to injury if those mitochondria are not working correctly.

Key Points: 
  • Specific kidney cells are rich in mitochondria and highly vulnerable to injury if those mitochondria are not working correctly.
  • Mitochondrial dysfunction is strongly implicated in kidney injury and chronic kidney disease (CKD).
  • Dr Suhail Nurbhai, CMO of Mission Therapeutics, commented: We are delighted that our lead programme is entering the clinic.
  • Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis.

Strive Health Names Ted Shannon Chief Financial Officer

Retrieved on: 
Thursday, March 31, 2022
General Health, Finance, Other Health, Health, Professional Services, Chronic kidney disease, LinkedIn, Infusion, Â, Carleton College, Growth, Multimedia, Business, CFO, ESKD, CEO, Shannon, Twitter, Tony F. Chan, CKD, Physician, Optum, Technology, Population health, Insurance, Management, Medicare

Strive Health, a national leader in value-based kidney care, has named Ted Shannon Chief Financial Officer.

Key Points: 
  • Strive Health, a national leader in value-based kidney care, has named Ted Shannon Chief Financial Officer.
  • Shannon will lead the companys financial operations and will direct strategic financial planning to support the companys growth.
  • Im excited to contribute to the companys mission and use my skills to help Strive continue its strong growth, Shannon said.
  • Strive Health is the nations leader in value-based kidney care and partner of choice for innovative healthcare payors and providers.

Satellite Healthcare and Dialyze Direct to Enter Strategic Collaboration, Expanding Cutting Edge Dialysis Services Across U.S.

Retrieved on: 
Wednesday, March 30, 2022
Nursing, Medical Devices, Seniors, Hospitals, Practice Management, Other Health, Managed Care, Health, Consumer, Chronic kidney disease, Method, Nephrology, Renal replacement therapy, Organization, Population, Dialysis, Kidney, Multimedia, Overalls, LOI, Small Satellite Research Laboratory, Health care, Research, Kidney disease, Health, Technology, CKD, Solution, SNF, Acquisition, Patient, Pharmaceutical industry, Medical device, Hospital, General number field sieve, Nursing, Medical Devices, Seniors, Hospitals, Practice Management, Other Health, Managed Care, Health, Consumer

Satellite Healthcare, which has attained the countrys highest rate of home dialysis usage among patients with end stage kidney disease, and Dialyze Direct, which leads the nation with the number of patients on dialysis in SNFs, plan to make significant care improvements for the dialysis patient population.

Key Points: 
  • Satellite Healthcare, which has attained the countrys highest rate of home dialysis usage among patients with end stage kidney disease, and Dialyze Direct, which leads the nation with the number of patients on dialysis in SNFs, plan to make significant care improvements for the dialysis patient population.
  • These strategic growth transactions enhance Dialyze Directs position as the leading SNF dialysis provider in the United States.
  • Dialyze Direct and Satellite Healthcare also intend to collaborate on research projects relating to dialysis, CKD and CKD management initiatives in the geriatric patient population.
  • Through its affiliated services, Satellite WellBound, Satellite Dialysis, and Satellite Research, Satellite Healthcare provides unparalleled kidney care services addressing patient wellness education, chronic kidney care management, and personalized clinical services.

Experienced Leaders in Value-Based Care Launch New Model in Duo Health to Address America’s Chronic Kidney Disease Crisis

Retrieved on: 
Wednesday, March 30, 2022
Nursing, Seniors, Finance, Professional Services, Practice Management, Family, Managed Care, General Health, Consumer, Health, Chronic kidney disease, Risk, Health equity, Health, Face, Trust, Population, Dialysis, Kidney, Patient, ESKD, Google Health, SCAN, Prevalence, Innovation, Technology, Chief executive officer, CPF, Machine learning, Time, Ageing, CKD, Physician, Transplant, Frazier Healthcare Partners, Solution, UCLA, IPO, AI, Blue Shield, Management, Healthcare, Pharmaceutical industry, Medicine

Duo Health is co-founded by CEO Nathan Goldstein, Dr. Stuart Levine and Chicago Pacific Founders (CPF).

Key Points: 
  • Duo Health is co-founded by CEO Nathan Goldstein, Dr. Stuart Levine and Chicago Pacific Founders (CPF).
  • Chicago Pacific Founders has made their mark in establishing businesses in value-based care to deliver innovative models in specialty care.
  • Duo Health (Duo) is a new type of medical group designed around the needs of patients with chronic kidney disease and their physicians.
  • The Duo Health team is comprised of leaders in value-based health care, technology and behavioral science who share a vision for advancing health equity one relationship at a time.

Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Retrieved on: 
Tuesday, March 29, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Risk, Therapy, Multiple sclerosis, Chronic kidney disease, Dialysis, ESRD, Trial of the century, United Kingdom, Kidney, Clinical trial, Chimeric antigen receptor T cell, Autoimmunity, HLA-A*02, University Medical Center Groningen, Survival, Research, Nephrotoxicity, Kidney transplantation, Holm–Bonferroni method, Cardiovascular disease, Medicine, CEO, Immune system, Safety, Technology, U.S. Securities and Exchange Commission, Hope, Inflammation, Nasdaq, COVID-19, Annual report, Patient, Cancer, Vaccine, Pharmaceutical industry, Sangamo Therapeutics, THE STEADFAST STUDY, SANGAMO THERAPEUTICS

I look forward to the dosing of more patients and seeing data from the study to understand the potential of TX200.

Key Points: 
  • I look forward to the dosing of more patients and seeing data from the study to understand the potential of TX200.
  • Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD) who must otherwise remain on long-term dialysis.
  • TX200 was designed with the potential to prevent kidney rejection by reducing local inflammation and promoting immunological tolerance to the graft.
  • This investigational cell therapy is being assessed in HLA-A2 negative patients receiving a mismatched HLA-A2 positive kidney from a living donor.

Worldwide Dialysis Industry to 2030 - Opportunity Analysis and Industry Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, March 25, 2022
Medical Devices, Health, Adoption, Industry, Co-production (public services), CAGR, Population, USD, Dialysis, Chronic kidney disease, Kidney, Peritoneal dialysis, Prevalence, Kidney cancer, Diabetes, Service, Solution, Awareness, Patient, Medical device, Health insurance

The "Dialysis Market by Type, by Product and Services and by End User - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dialysis Market by Type, by Product and Services and by End User - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Dialysis is a technique used to remove the waste material from the body among the patients of kidney damage.
  • Growing prevalence of chronic kidney diseases, high demand for the advanced dialysis solutions, and increasing new product launches in home dialysis category are driving the global dialysis market growth.
  • Moreover, preference for the peritoneal dialysis and increasing adoption of home-based dialysis products are important trend of the global dialysis market that are expected to usher numerous opportunities in the near future.